Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences

SAN DIEGO, June 22, 2011 /PRNewswire/ -- Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody drug conjugate (ADC) programs at five upcoming scientific conferences. The presentations will include data obtained from recent xenograft studies comparing Ambrx ADCs with those created using other technologies.

"Ambrx technology has been clinically validated as safe and efficacious for creating PEGylated proteins, and we have recently focused our efforts on creating site-specific conjugates of antibodies with best-in-class potential," Dr. Cho said. "Preclinical data obtained from partnered and unpartnered programs show us that the application of our technology to creating ADCs has tremendous potential. We look forward to presenting this promising data to the scientific community over the coming months."

At the IBC Life Sciences' Next Generation Protein Therapeutics Summit in San Francisco, Dr. Cho will deliver a presentation titled "Synthetic Biology Applied to Biotherapeutics" at 1:30 p.m. PDT on June 22, 2011.

At the American Chemical Society's 242nd National Meeting in Denver, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry with an Expanded Genetic Code" at 9 a.m. MDT on August 29, 2011.

At the Cambridge Healthtech Institute's PEGs Europe conference in Hannover, Germany, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry Applied to Antibody Drug Conjugates" at 3:05 p.m. CEST on October 11, 2011.

At the World Antibody Drug Conjugate Summit in San Francisco, Dr. Cho will deliver a presentation titled "Optimized Antibody Drug Conjugates with an Expanded Genetic Code" at 10 a.m. PDT on October 27, 2011.

Dr. Cho will also deliver a presentation at the IBC Life Sciences' Empowered Antibody Therapies Conference, held August 1-3, 2011, in San Francisco.

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its broad biologics platform to create best-in-class therapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx is developing several product candidates in collaboration with Eli Lilly and Company, including a Phase 3 compound expected to be launched commercially in 2013. The company has validated its biologics platform through additional partnerships with Pfizer and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220
[email protected]
[email protected]

SOURCE Ambrx Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED